Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

NCT00779389 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Non Small Cell Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Dasatinib + Placebo
DRUG: Erlotinib plus Dasatinib
DRUG: Placebo
DRUG: Erlotinib

Sponsor

University of Pittsburgh